The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Ardy Davarifar
No Relationships to Disclose
 
Yana Najjar
Consulting or Advisory Role - Bristol Myers Squibb; Immunocore; InterVenn Biosciences; Mallinckrodt/Therakos; Merck; Pfizer
Speakers' Bureau - Immunocore; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer/EMD Serono (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Istari
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Agenus (Inst); Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Michael Wong
Consulting or Advisory Role - Castle Biosciences; Incyte; Regeneron; Replimune
 
Nikhil Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron; Replimune
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; T-knife Therapeutics
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; Immunocore; Italfarmaco; Lunaphore Technologies; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre; Replimune
 
Tawnya Bowles
Research Funding - Amgen (Inst); Genentech (Inst)
Other Relationship - Natera
 
Mark Navarro
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Giuseppe Gullo
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Honoraria - Bristol-Myers Squibb; Egle; IO Biotech; MaaT Pharma; Merck; MSD; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche; Sanofi; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Bristol-Myers Squibb; Egle; MaaT Pharma; Merck; MSD; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche; Sanofi; Sun Pharma; Ultimovacs
Travel, Accommodations, Expenses - Pierre Fabre